drugset
drugset / Trial / NCT02462603

Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease

NCT02462603 ↗

Phase 2 Completed 44 enrolled Edison Pharmaceuticals Inc
NaSingle-groupOpen-labelTreatment

Summary

Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.

Timeline

Start
2016-05-17
Primary completion
2019-01-08
Completion
2019-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PTC-589 Unknown 500 mg Oral

Indications

Parkinson disease